65 related articles for article (PubMed ID: 11914886)
21. Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome.
Kiviniemi A; Gardberg M; Kivinen K; Posti JP; Vuorinen V; Sipilä J; Rahi M; Sankinen M; Minn H
Oncotarget; 2017 Jul; 8(30):49123-49132. PubMed ID: 28467778
[TBL] [Abstract][Full Text] [Related]
22. Somatostatin receptor subtype 2 in high-grade gliomas: PET/CT with (68)Ga-DOTA-peptides, correlation to prognostic markers, and implications for targeted radiotherapy.
Kiviniemi A; Gardberg M; Frantzén J; Pesola M; Vuorinen V; Parkkola R; Tolvanen T; Suilamo S; Johansson J; Luoto P; Kemppainen J; Roivainen A; Minn H
EJNMMI Res; 2015; 5():25. PubMed ID: 25977882
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P--results from a phase I study.
Cordier D; Forrer F; Kneifel S; Sailer M; Mariani L; Mäcke H; Müller-Brand J; Merlo A
J Neurooncol; 2010 Oct; 100(1):129-36. PubMed ID: 20217458
[TBL] [Abstract][Full Text] [Related]
24. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial.
Cordier D; Forrer F; Bruchertseifer F; Morgenstern A; Apostolidis C; Good S; Müller-Brand J; Mäcke H; Reubi JC; Merlo A
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1335-44. PubMed ID: 20157707
[TBL] [Abstract][Full Text] [Related]
25. Genomic biomarkers for molecular imaging: predicting the future.
Thakur ML
Semin Nucl Med; 2009 Jul; 39(4):236-46. PubMed ID: 19497401
[TBL] [Abstract][Full Text] [Related]
26. Individual voxelwise dosimetry of targeted 90Y-labelled substance P radiotherapy for malignant gliomas.
Kneifel S; Bernhardt P; Uusijärvi H; Good S; Plasswilm L; Buitrago-Téllez C; Müller-Brand J; Mäcke H; Merlo A
Eur J Nucl Med Mol Imaging; 2007 Sep; 34(9):1388-95. PubMed ID: 17265035
[TBL] [Abstract][Full Text] [Related]
27. Radiation protection in radionuclide therapies with (90)Y-conjugates: risks and safety.
Cremonesi M; Ferrari M; Paganelli G; Rossi A; Chinol M; Bartolomei M; Prisco G; Tosi G
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1321-7. PubMed ID: 16832636
[TBL] [Abstract][Full Text] [Related]
28. Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression.
Carlsson J; Ren ZP; Wester K; Sundberg AL; Heldin NE; Hesselager G; Persson M; Gedda L; Tolmachev V; Lundqvist H; Blomquist E; Nistér M
J Neurooncol; 2006 Mar; 77(1):33-45. PubMed ID: 16200342
[TBL] [Abstract][Full Text] [Related]
29. Targeted radiotherapy of brain tumours.
Zalutsky MR
Br J Cancer; 2004 Apr; 90(8):1469-73. PubMed ID: 15083170
[TBL] [Abstract][Full Text] [Related]
30. Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002.
de Jong M; Kwekkeboom D; Valkema R; Krenning EP
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):463-9. PubMed ID: 12569416
[TBL] [Abstract][Full Text] [Related]
31. [Iridium 192 brachytherapy of supra-tentorial high grade glioma recurring in irradiated areas: technique and preliminary results of the Pitié-Salpêtrière hospital group].
Boisserie G; Cornu P; Dormont D; Sahel M; Hardiman C; Tep B; Mandin AM; Barret C; Faillot T; Delattre JY; Monjour A; Poisson M; Marsault C; Philippon J; Simon JM; Baillet F; Mazeron JJ
Bull Cancer Radiother; 1996; 83(3):144-52. PubMed ID: 8977564
[TBL] [Abstract][Full Text] [Related]
32. Positron emission tomography for radiation treatment planning.
Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
[TBL] [Abstract][Full Text] [Related]
33. Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study.
Schumacher T; Hofer S; Eichhorn K; Wasner M; Zimmerer S; Freitag P; Probst A; Gratzl O; Reubi JC; Maecke R; Mueller-Brand J; Merlo A
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):486-93. PubMed ID: 11914886
[TBL] [Abstract][Full Text] [Related]
34. Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas.
Merlo A; Hausmann O; Wasner M; Steiner P; Otte A; Jermann E; Freitag P; Reubi JC; Müller-Brand J; Gratzl O; Mäcke HR
Clin Cancer Res; 1999 May; 5(5):1025-33. PubMed ID: 10353735
[TBL] [Abstract][Full Text] [Related]
35. Successful diffusible brachytherapy (dBT) of a progressive low-grade astrocytoma using the locally injected peptidic vector and somatostatin analogue [90Y]-DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC).
Hofer S; Eichhorn K; Freitag P; Reubi JC; Muller-Brand J; Maecke H; Merlo A
Swiss Med Wkly; 2001 Nov; 131(43-44):640-4. PubMed ID: 11835112
[TBL] [Abstract][Full Text] [Related]
36. [Yttrium 90 DOTATOC: a new somatostatin analog for cancer therapy of neuroendocrine tumors].
Otte A; Herrmann R; Mäcke HR; Müller-Brand J
Praxis (Bern 1994); 1999 Aug; 88(31-32):1263-8. PubMed ID: 10479965
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
